Analysis of the impact of the MDD (Medical Device Directive) review amendments on active implants
This article was originally published in Clinica
The changes proposed by the European Commission and the European Parliament to the Active Implantable Medical Device Directive (AIMDD) relating to active implantable medical devices (90/385) are more fundamental than the current proposals to revise the Medical Devices Directive (MDD - 93/42). So says vice-president of Quintiles Consulting Mika Reinikainen, who reports on the main amendments to the AIMDD proposed at the Parliament's March 29 session
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.